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Potentially inappropriate prescribing among older
people in the United Kingdom
Marie C Bradley5*, Nicola Motterlini2ˆ, Shivani Padmanabhan4, Caitriona Cahir3, Tim Williams4, Tom Fahey2
and Carmel M Hughes1
Abstract
Background: Potentially inappropriate prescribing (PIP) in older people is associated with increases in morbidity,
hospitalisation and mortality. The objective of this study was to estimate the prevalence of and factors associated
with PIP, among those aged ≥70 years, in the United Kingdom, using a comprehensive set of prescribing indicators
and comparing these to estimates obtained from a truncated set of the same indicators.
Methods: A retrospective cross-sectional study was carried out in the UK Clinical Practice Research Datalink (CPRD),
in 2007. Participants included those aged ≥ 70 years, in CPRD. Fifty-two PIP indicators from the Screening Tool of
Older Persons Potentially Inappropriate Prescriptions (STOPP) criteria were applied to data on prescribed drugs and
clinical diagnoses. Overall prevalence of PIP and prevalence according to individual STOPP criteria were estimated.
The relationship between PIP and polypharmacy (≥4 medications), comorbidity, age, and gender was examined. A
truncated, subset of 28 STOPP criteria that were used in two previous studies, were further applied to the data to
facilitate comparison.
Results: Using 52 indicators, the overall prevalence of PIP in the study population (n = 1,019,491) was 29%.
The most common examples of PIP were therapeutic duplication (11.9%), followed by use of aspirin with no
indication (11.3%) and inappropriate use of proton pump inhibitors (PPIs) (3.7%). PIP was strongly associated with
polypharmacy (Odds Ratio 18.2, 95% Confidence Intervals, 18.0-18.4, P < 0.05). PIP was more common in those
aged 70–74 years vs. 85 years or more and in males. Application of the smaller subset of the STOPP criteria resulted
in a lower PIP prevalence at 14.9% (95% CIs 14.8-14.9%) (n = 151,598). The most common PIP issues identified
with this subset were use of PPIs at maximum dose for > 8 weeks, NSAIDs for > 3 months, and use of long-term
neuroleptics.
Conclusions: PIP was prevalent in the UK and increased with polypharmacy. Application of the comprehensive
set of STOPP criteria allowed more accurate estimation of PIP compared to the subset of criteria used in previous
studies. These findings may provide a focus for targeted interventions to reduce PIP.
Keywords: Potentially inappropriate prescribing, Older people, Screening tool of older persons potentially
inappropriate Prescriptions (STOPP), CPRD
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Background
Appropriate medications in older people have a clear
evidence-based indication, are well tolerated and are
cost-effective. In contrast, medicines that are potentially
inappropriate, lack evidence-based indications, pose a
higher risk of adverse effects or are not cost-effective [1].
Appropriateness of prescribing in older people has
been most extensively assessed by process measures
(provider’s actions) [2]. Explicit process measures are
criterion-based and indicate drugs to be avoided in older
people, independent of diagnoses or in the presence of
certain diagnoses [3-5]. Explicit measures, requiring little
clinical detail, can often be applied to large prescribing
databases [2].
The United States (US) Beers criteria, the most com-
monly used explicit process measure for assessing poten-
tially inappropriate prescribing (PIP) in older people, has
been widely validated [6,7], but has some limitations; for
example, approximately 50% of the Beers drugs are
unavailable in European countries [8]. The recently
developed ‘Screening Tool of Older Persons potentially
inappropriate Prescriptions’ (STOPP) provides a more
comprehensive explicit process measure of PIP, is vali-
dated for use in European countries [9], and overcomes
some of the limitations inherent in the Beers criteria.
STOPP is a physiological system-based screening tool
comprising 65 clinically significant criteria which take
drug-drug and drug-disease interactions, drug doses and
duration of treatment into consideration. It considers
clinical effectiveness and the removal of any potentially
unnecessary drugs as well as drug duplication.
Optimisation of drug prescribing for older people is
essential due to the substantial clinical and economic
implications of drug-induced illness. PIP in older people
has been associated with significant morbidity, adverse
drug events (ADEs), hospitalisation and mortality [10-13].
PIP prevalence rates in older people have ranged from 14%
to 37% in the US and Canada respectively, 19.8% in Europe
[14] and 28% in the United Kingdom (UK) using the Beers
criteria [15]. Further studies of PIP in the UK using large
representative national databases, to identify the most
common national PIP issues have been called for [15].
Previous studies of PIP have been limited to using a
truncated version of the STOPP criteria due to a lack of
clinical data in the available databases [16,17]. These
studies used prescribing databases to investigate PIP in
Northern Ireland (NI) and the Republic of Ireland (ROI).
However, failure to apply the more complete set of
STOPP criteria may have led to an underestimation of
PIP and failure to identify important instances of PIP.
Using the Clinical Practice Research Datalink (CPRD),
the world’s largest computerized database of anonymized
longitudinal patient records from primary and secondary
care, may overcome this problem. As CPRD provides a
complete record of clinical and prescribing data, a more
comprehensive set of criteria can be applied which may
more accurately reflect PIP prevalence.
Therefore, the overall aim of this study was to estimate
the prevalence of PIP, in older people, in the UK, by
applying a comprehensive set of 52 of the European
based STOPP criteria to the CPRD and then to compare
this to estimates obtained from applying the truncated
version of the criteria to the same data. We also sought to
determine the effect of factors such as polypharmacy, age,
sex and co-morbidity on the prevalence of PIP which
other studies have reported to be significant [16,17].
Methods
Setting
CPRD data from 2007 were used to examine PIP among
older people, in a cross sectional study design, in the
UK, using 52 of the 65 STOPP criteria, which have been
described previously [9]. The term ‘UK’ will be used to
refer to the findings resulting from the CPRD database
throughout this paper. As stated in the Background,
CPRD is the world’s largest computerized database of
anonymized longitudinal patient records from primary
care. It collects data from around 660 general practices
in the UK, covers about 8.5% of the population and is
broadly representative in terms of age, sex and geography.
As of March 2013, there were 12.6 million acceptable
(research quality) patients, of which 5.4 million are active
(alive and registered with a contributing general practice).
Demographic information, lifestyle data, prescription
details, clinical events and diagnoses, preventive care,
specialist referrals, and hospital admissions and their
major outcomes are all recorded in the database [18].
Data comes from up-to-standard (UTS) general prac-
tices, described as those that meet pre-defined standards
in terms of data quality and collection. The high quality
of CPRD prescription and diagnosis information has
been documented [19,20]. Ethical approval for all obser-
vational research using CPRD data has been obtained
from a Multicenter Research Ethics Committee. Data were
extracted in February 2012.
Participants
The study population comprised all CPRD patients aged
70 years or older registered with an UTS practice during
the study period 01/01/2007- 31/12/2007. All patients
were required to have at least 3 months of lead-in data,
prior to 01/01/2007, to ascertain long term use of
certain medications. All data were anonymised and the
research team had no access to any identifiable data.
Exposures
Fifty two of the 65 STOPP indicators were deemed suit-
able for application to CPRD clinical and therapy data
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based on the available information. Some indicators
could not be applied due to absence of certain types of
clinical data. For example, “Long-term opiates in those
with dementia unless indicated for palliative care or ma-
nagement of moderate/severe chronic pain syndrome”
was difficult to ascertain and therefore, were not used.
However, the availability of clinical as well as prescription
information allowed a larger number of STOPP criteria to
be applied than in previous studies [16,17]. Exposure
status was based on prescription and clinical data in the
database. Data on drug use were extracted using Multilex
codes whilst clinical diagnoses were identified from Read
codes. All codes were manually reviewed and confirmed
by MB and an experienced primary care physician.
Patients were categorised into those who received a
STOPP criteria drug or drug combination. STOPP
criteria which specified a particular dosage not to be
exceeded e.g. proton pump inhibitors (PPIs) at ma-
ximum therapeutic dosage for > 8 weeks, were evaluated
by calculating the number of defined daily doses (DDDs)
[21] for each recipient according to the DDD of the
drug, and the strength and quantity of the dispensed
medication for each prescription. A subset of 28 STOPP
criteria which had been used in two previous investiga-
tions [16,17] were also applied to the data.
Polypharmacy
The total number of prescriptions received for each dif-
ferent drug class was calculated for each participant,
during the study period. A repeat medication was
defined by receipt of 3 or more prescriptions for that
agent in the study period. Polypharmacy was indicated
by use of 4 or more repeat medications, each from dif-
ferent drug groups [22].
Charlson comorbidity index
In order to investigate the potential effect of co-morbid
conditions on PIP, we applied the Charlson comorbidity
index (CCI) to the CPRD data. The CCI is the most
widely studied morbidity index and its validity has been
confirmed by comparison with other indices [23,24]. It
has also been validated for application to longitudinal
databases [25]. The CCI takes account of both the
number and severity of the comorbid conditions.
Outcomes
The main outcome was the overall prevalence of PIP in
those aged ≥70 years in 2007 in the UK, according to
the comprehensive set of 52 STOPP criteria and the
subset of 28 criteria. Secondary outcome measures were:
(i) the prevalence of PIP per individual STOPP criterion,
and (ii) the association between PIP, polypharmacy, CCI,
gender, and age group.
Statistical analysis
The overall prevalence of PIP, the corresponding 95%
Confidence intervals (CIs) and the prevalence per indi-
vidual STOPP criterion were calculated. Logistic regres-
sion analyses were used to determine the association
between any (vs. no) PIP and polypharmacy (categorized
as no polypharmacy vs polypharmacy), CCI (categorized
as 0, 1, 2, 3, 4 points assigned), age group (70 to 74 years,
75 to 80 years, 81 to 85 years, 85+ years), and gender.
Adjusted odds ratios (OR) and 95% confidence intervals
(CI) were calculated. Data extraction and analysis were
performed using STATA Version 12 (Timberlake Con-
sultants Ltd, London, UK).
Results
1,019,491 persons, aged ≥ 70 years, identified in the CPRD,
were eligible for inclusion in the study. More than 50%
were female (592,045, 58%) and 78.5% (799,948) were
aged ≥ 75 years as shown in Table 1.
Main outcomes
Overall prevalence of PIP in the UK in 2007 using 52 STOPP
criteria
The overall prevalence of PIP in the UK, according to the
52 STOPP indicators, was 29% (95%CIs 28- 29%) (n =
295,653). Just under 29% (28.7%) of males had PIP in the
study period compared to 29.2% of females. Of those aged
70–74, 37.4% had a PIP compared to 16% of those aged >
85 years. (Table 1) Almost 15% of the population, (148,614
patients) were prescribed one potentially inappropriate
medication, 77,923 (7.6%) were prescribed two and 69,116
(6.8%) were prescribed three or more.
Prevalence of PIP according to individual STOPP criteria
Table 2 describes the prevalence for each individual
STOPP criteria, listed by physiological system. The most
common issue of PIP was therapeutic duplication
(121,668 patients 11.9%), followed by use of aspirin with
no history of coronary, cerebral or peripheral vascular
symptoms or occlusive arterial event (115,576 patients
11.3%). Use of PPIs at maximum therapeutic dose for >
8 weeks (38,153 patients, 3.7%) was the third most com-
mon PIP, whilst alpha blockers with long-term urinary
catheter in situ (31,226 patients 3.1%) was next. Many
other criteria had a prevalence less than 0.5%.
There was strong evidence of an association between
PIP and polypharmacy. Those receiving 4 or more repeat
medications were 18 times more likely to be exposed to
PIP compared to those on 0–3 medications (OR 18.2,
95% CI, 18.0-18.4, P < 0.05). The odds of having a PIP
was only slightly lower in females compared to males
when adjusting for other factors (OR 0.9 95% CI 0.9-
0.9, P < 0.05). PIP was less common in those aged
85 years and above compared to those aged 70–74 years
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(OR 0.5, 95% CI, 0.4-0.5, P < 0.05). PIP was more
common in those with fewer co-morbid conditions
according to the CCI (Table 3).
Prevalence of PIP using 28 STOPP criteria
The prevalence of PIP in the UK was 14.9% (95% CIs
14.8-14.9%) (n = 151,598) when the subset of 28 STOPP
indicators was applied. Just under 11% (109,808 patients)
were in receipt of at least one case of PIP, whilst 3.1%
(31,693 patients) were exposed to 2 or more instances
and 1.0% (10,095 patients) were exposed to three or
more. The most common PIP issues were use of PPIs at
maximum therapeutic dose for > 8 weeks (3.7%, 38,153
patients), NSAIDs for > 3 months (3.2% 32,373 patients),
and use of long-term neuroleptics (2.1%, 21,012 patients.
Discussion
Following the application of 52 STOPP indicators to
CPRD, the overall PIP prevalence, in those aged ≥
70 years, in the UK, was estimated at 29%. The most
common cases of PIP were therapeutic duplication, use
of aspirin with no valid indication and inappropriate use
of PPIs. PIP was associated with polypharmacy and was
less common among those 85 years and above compared
to younger age groups. It was also slightly more com-
mon in men. When a subset of 28 STOPP criteria, com-
monly used in other studies, were applied, the overall
PIP prevalence for the UK was 14.9%. The most com-
mon instances of PIP on application of the subset were
PPI use at maximum dose for greater than 8 weeks and
the use of NSAIDs for > 3 months. Application of the 52
STOPP indicators in CPRD enabled a more comprehen-
sive estimation of PIP and highlighted additional PIP
issues that were not observed with the truncated version
of the criteria.
PIP in the UK (application of 52 indicators)
Therapeutic duplication and inappropriate use of aspirin
with no valid indication were the most prevalent cases
of PIP in the UK and have also been reported as preva-
lent among older hospitalised patients in Ireland [13].
Therapeutic duplication is difficult to conclusively iden-
tify in a medical record database as drugs, which have
been switched within a therapeutic group, may appear
on the medical record for a number of months following
changes, even though they are not dispensed. The prac-
tice of prescribing aspirin to asymptomatic individuals
for the prevention of myocardial infarction is common
and may have influenced these findings. However, this
practice has been questioned after a meta-analysis on
the subject reported no benefit [26,27]. Inappropriate
use of PPIs has been reported previously and targeting
such use is critical to reducing the burden of PIP in
older people [28-30].
Table 1 Descriptive characteristics of the study
population in CPRD
PIP
(n = 723,838)
No PIP
(n = 295,653)
Gender
-Male (%) 122,817 (28.7) 304,622 (71.3)
-Female (%) 172,834 (29.2) 419,211 (70.8)
-Missing (%) 2
Age (years)
-70–74 (%) 82,177 (37.4) 137,366 (62.6)
-75–80 (%) 92,488 (37.6) 153,778 (62.4)
-81–85 (%) 62,407 (33.1) 126,040 (66.9)
- > 85 (%) 58,581 (18) 306,654 (84)
Morbidities
(Charlson morbidity index score)
-1 (%) 189,864 (28.3) 481,983 (71.7)
-2 (%) 52,365 (46.8) 59,519 (53.2)
-3 (%) 53,424 (22.7) 182,336 (77.3)
Polypharmacy (≥4 medications)
-Never (%) 114,816 (14.6) 669,572 (85.3)
-Ever (%) 180,837 (76.9) 54,266 (23.1)
Chronic Obructive Pulmonary Disease
-No (%) 277,497 (28.2) 707,447 (71.8)
-Yes (%) 18,156 (52.6) 16,391 (47.5)
Peptic ulcer
-No (%) 274,487 (28.9) 675,938 (71.1)
-Yes (%) 21,166 (30.7) 47,900 (69.4)
Diabetes
-No (%) 225,280 (27.3) 625,591 (72.7)
-Yes (%) 70,373 (41.7) 98,247 (58.3)
Dementia
-No (%) 283,983 (28.5) 710,985 (71.5)
-Yes (%) 11,670 (47.6) 12,853 (52.4)
Hypertension
-No (%) 140,467 (21.1) 525,316 (78.9)
-Yes (%) 155,186 (43.9) 198,522 (56.1)
Osteoarthritis
-No (%) 216,981 (26.5) 601,325 (73.5)
-Yes (%) 78,672 (39.1) 122,513 (60.9)
Heart failure
-No (%) 292,294 (29.0) 715,868 (71.0)
-Yes (%) 3,359 (29.7) 7,970 (70.4)
Parkinsonism
-No (%) 290,071 (29.0) 709,721 (71.0)
-Yes (%) 5,582 (28.3) 14,117 (71.7)
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Table 2 Prevalence of potentially inappropriate prescribing by individual STOPP criteria among older people
in CPRD
Criteria description Number of patients
(N = 1,019,491)
% of patients
(95% CIs)
Cardiovascular system
Digoxin > 125 mcg/day (increased risk of toxicity)a 9327 0.9 (0.8-0.9)
Thiazide diuretics with gout (exacerbates gout) 6094 0.6 (0.6-0.6)
Beta-blocker + verapamil (risk of symptomatic heart block) 503 0.05 (0.05-0.05)
Aspirin +Warfarin without a PPI/ H2RA (high risk of gastrointestinal bleeding) 3616 0.4 (0.3 -0.4)
Dipyridamole as monotherapy for cardiovascular secondary prevention (no evidence of efficacy) 2137 0.2 (0.2-0.2)
Aspirin > 150 mg/day (increased bleeding risk) 5128 0.5 (0.5-0.5)
Loop diuretic for dependent ankle oedema only i.e. no clinical signs of heart failure (no evidence of efficacy,
compression hosiery usually more appropriate)
25843 2.54 (2.5-2.6)
Loop diuretic as first-line monotherapy for hypertension (safer, more effective alternatives available) 7128 0.7 (0.7-0.7)
Non-cardioselective beta-blocker with Chronic Obstructive Pulmonary Disease (COPD) (risk of bronchospasm) 353 0.03 (0.03-0.03)
Calcium channel blockers with chronic constipation (may exacerbate constipation) 16826 1.6 (1.6-1.7)
Aspirin with a past history of peptic ulcer disease without histamine H2 receptor antagonist or Proton Pump
Inhibitor (risk of bleeding)
3912 0.4 (0.4-0.4)
Aspirin with no history of coronary, cerebral or peripheral vascular symptoms or occlusive arterial event
(not indicated)
115576 11.3 (11.3-11.4)
Central Nervous System
TCAs with dementia (worsening cognitive impairment) 354 0.03 (0.03-0.03)
TCAs with glaucoma (exacerbate glaucoma) 354 0.03 (0.03-0.03)
TCAs with opioid or calcium channel blocker (risk of severe constipation) 26649 2.6 (2.6-2.6)
Long-term (>1 month) long-acting benzodiazepines (risk of prolonged sedation, confusion,
impaired balance, falls)
15057 1.5 (1.5-1.5)
Long-term (>1 month) neuroleptics (antipsychotics) (risk of confusion, hypotension, extrapyramidal
side-effects, falls)
21012 2.1 (2.1-2.1)
Long- term (>1 month) neuroleptics with parkinsonism (worsen extrapyramidal symptoms) 852 0.1 (0.1-0.1)
Anticholinergics to treat extrapyramidal symptoms of neuroleptic medications
(risk of anticholinergic toxicity)
869 0.1 (0.1-1.0)
Phenothiazines with epilepsy (may lower seizure threshold) 448 0.04 (0.04-0.04)
Prolonged use (>1 week) of first-generation anti-histamines (risk of sedation and anti-cholinergic
side-effects)
6020 0.6 (0.6-0.6)
TCA’s with cardiac conductive abnormalities 543 0.05 (0.05-0.05)
TCA’s with prostatism or prior history of urinary retention (risk of urinary retention) 2623 0.3 (0.3-0.3)
TCA’s with constipation (likely to worsen constipation) 7279 0.7 (0.7-0.7)
Gastrointestinal System
Prochlorperazine or metoclopramide with parkinsonism (risk of exacerbating parkinsonism) 385 0.04 (0.04)
PPI for peptic ulcer disease at maximum therapeutic dosage for > 8 weeks (dose reduction or earlier
discontinuation indicated)
38153 3.7 (3.7-3.8)
Anticholinergic antispasmodic drugs with chronic constipation (risk of exacerbation of constipation) 1208 0.1 (0.1-0.1)
Respiratory system
Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-severe
COPD (unnecessary exposure to long-term side-effects of systemic steroids)
1339 0.1 (0.1-0.1)
Nebulised ipatropium with glaucoma (exacerbate glaucoma) 20 0
Musculoskeletal system
Long term NSAID use (>3 months) with osteoarthritis (simple analgesics preferable) 12167 1.2 (1.2-1.2)
Warfarin and NSAID use (risk of gastrointestinal bleeding) 2495 0.2 (0.2-0.3)
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The strong association between PIP and polypharmacy
seen in this study has been reported elsewhere and the
literature is replete with studies consistently demonstra-
ting this association [31-34]. Polypharmacy is a common
phenomenon in older adults, and whilst targeting
polypharmacy represents an obvious approach to redu-
cing PIP, the distinction between appropriate and
inappropriate polypharmacy is not clearly defined [22].
One study demonstrated that despite rises in poly-
pharmacy in the UK, largely suspected to be associated
with better chronic disease management, no sub-
sequent increase in PIP was seen, indicating that
prescribing more medications does not always translate
to a rise in PIP [15]. In this era of increased focus on
chronic disease management and multi-morbidities, this
is an on-going challenge for those responsible for prescri-
bing in primary care.
This study revealed that PIP was less common as pa-
tients aged and this has also been widely documented
[35,36]. Greater physician awareness of PIP in the oldest
old and the higher mortality rate in this age group, as
well as changing clinical priorities at the end of life have
been postulated as potential explanations [37]. In this
study, PIP was less likely in those with a higher score on
the CCI compared to lower scores. This may also be
related to advancing age as those who are older receive
an additional rating on the CCI.
PIP in the UK (application of 28 indicators)
As expected, application of the smaller subset of STOPP
criteria to the CPRD data resulted in a lower prevalence
of PIP. However, some of the most common instances of
PIP differed from those identified using the larger set of
criteria. As seen in previous studies [16,17], using this
subset of criteria, tended to limit the investigation of PIP
and may result in a failure to target important areas of
prescribing that need attention in order to reduce the
overall problem. The previous studies which applied this
subset of criteria investigated PIP in NI and ROI [16,17].
Compared to those studies, the UK had a much lower
Table 2 Prevalence of potentially inappropriate prescribing by individual STOPP criteria among older people
in CPRD (Continued)
Non-steroidal anti-inflammatory drug (NSAID) with history of peptic ulcer disease or gastrointestinal bleeding,
unless with concurrent histamine H2 receptor antagonist, PPI or misoprostol (risk of peptic ulcer relapse)
1040 0.1 (0.1-0.1)
NSAID with heart failure (risk of exacerbation of heart failure) 409 0.04 (0.04-0.04)
NSAID with chronic renal failure (risk of deterioration in renal function) 928 0.1 (0.1-0.1)
Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthrtitis or osteoarthritis
(risk of major systemic corticosteroid side-effects)
718 0.1 (0.1-0.1)
Long-term NSAID or colchicine for chronic treatment of gout where there is no contraindication to
allopurinol (allopurinol first choice prophylactic drug in gout)
2845 0.3 (0.3-0.3)
Urinary System
Antimuscarinic drugs (urinary) with dementia (risk of increased confusion and agitation) 297 0.03 (0.03-0.03)
Antimuscarinic drugs with chronic glaucoma (risk of acute exacerbation of glaucoma) 109 0.01 (0.01-0.01)
Bladder antimuscarinic drugs with chronic constipation (risk of exacerbation of constipation) 3514 0.3 (0.3-0.4)
Bladder antimuscarinic drugs with chronic prostatism (risk of urinary retention) 2791 0.3 (0.3-0.3)
Alpha-blockers in males with frequent incontinence i.e. one or more episodes of incontinence daily
(risk of urinary frequency and worsening of incontinence)
1426 0.1 (0.1-0.2)
Alpha-blockers with long-term urinary catheter in situ i.e. more than 2 months (drug not indicated) 31226 3.1 (3.0-3.1)
Endocrine system
Beta-blockers in those with diabetes mellitus and frequent hypoglycaemic episodes
(risk of masking hypoglycaemic symptoms)
26563 2.6 (2.6-2.6)
Glibenclamide with type 2 diabetes mellitus (risk of prolonged hypoglycaemia) 981 0.1 (0.1-0.1)
H. Drugs that adversely affect those prone to falls (≥1 fall in past three months) 0.3 (0.3-0.3)
1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance) 3358 0.2 (0.2-0.3)
2. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism) 2491
3. Firstgeneration antihistamines (sedative, may impair sensorium) 250 0.02 (0.02-0.02)
4. Vasodilator drugs (postural hypotension) 788 0.1 (0.1-0.1)
5. Long-term opiates in those with recurrent falls 10321 1.0 (0.1-1.0)
Two concurrent drugs from the same group- therapeutic duplication (optimization of monotherapy
within a single drug class)
121668 11.9 (11.9-12.0)
aItalised text in brackets represents the potential risk associated with the PIP indicators.
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overall prevalence of PIP (14.9%) [NI (34%) [16] and
ROI (36%)] [17]. The number of patients in receipt of 2
or more instances of PIP was also lower in the UK com-
pared to NI and ROI. The PPI and NSAIDs indicators
were the most common for all three jurisdictions, how-
ever, there were marked differences in prevalence, notably
in the PPI indicator. The comparative prevalence rates
were 16.69% in ROI, 10.79% in NI and 3.74% in the UK.
NI has a similar healthcare system to the rest of the
UK, yet the overall prevalence of PIP in NI was more
similar to that reported in ROI, despite differences in
their respective healthcare systems. Other studies that
compared prescribing in the NI and ROI have reported
commonalities [38]. The prevalence of certain criteria
(use of long-term long-acting benzodiazepines) was high
in NI and ROI (6.1% and 5.2% respectively) [16,17], yet
much lower in the UK using the CPRD data (1.5%).
Intensive prescribing initiatives in parts of the UK
(excluding NI), as early as 1988 [39], to reduce inappro-
priate benzodiazepine prescribing, may have accounted
for these differences and benzodiazepine dispensing de-
creased by 51.3% between 1980 and 2009, in England
alone [40]. It has been suggested that the legacy of civil
disturbances in NI, from previous decades, may have
influenced patterns of benzodiazepine prescribing in
this jurisdiction [41]. This highlights the multitude of
factors influencing PIP, many of which may be difficult
to modify.
The differences in PIP between regions may have been
influenced by region-specific regulatory measures, as
referred to in relation to benzodiazepines above. It has
been suggested that implementation of prescribing
guidelines and audits by clinical pharmacists may have
contributed to the lower prevalence of PIP observed in
the UK [14]. One study, which investigated PIP in nur-
sing home residents across eight European countries,
found a strikingly low PIP prevalence in Denmark com-
pared to other European countries, despite high rates of
polypharmacy [14].This low level was linked to the
provision of a drug utilization review by the National
Institute of Health, which included feedback to indivi-
dual physicians. This raises the question of whether a
more concerted effort between neighboring regions in
developing policies to tackle PIP might be useful.
Strengths and limitations
This is the largest study to date to investigate PIP in the
UK. Prospectively collected prescription and clinical data
from the CPRD, as well as accurate dosing information
increased the reliability of the findings compared to pre-
vious studies. The availability of clinical data allowed
more complete assessment of PIP. The use of a large
national database gave a clear insight into the more
common issues in PIP nationally rather than the local
focus of some previous studies [15].
The STOPP criteria were designed for application in
primary care settings with easy access to the patient’s full
medical record. Despite the comprehensive patient infor-
mation in CPRD, not all of the STOPP criteria could be
applied. Failure to apply the full criteria may have
resulted in overestimation of PIP in these instances.
In contrast, CPRD is a widely used and validated data-
base with reliable prescription and clinical information
collected from UTS practices across the UK. Whilst
CPRD is representative of the UK population, the gener-
alisability of the data may be limited by the fact that
those practices that contribute to the database, meet
pre-defined data and record-keeping quality standards. It
is possible that such practices might also deliver
enhanced quality prescribing which is less likely to be
inappropriate compared to an average non-CPRD practice.
Identification of Read codes for clinical diagnoses was
often ambiguous. This may have led to over- or under-
estimation of the prevalence of some criteria. In order to
reduce this potential misclassification, we sought the
assistance of an experienced primary care physician who
reviewed the codes. Therapeutic duplication, the most
common example of PIP in this study, was difficult to
accurately assess using medical record or prescription
databases and may have been misrepresented. Whilst we
Table 3 Unadjusted and adjusted ORs for the association
between PIP and its predictors
PIP (ever/never) Unadjusted odds
ratios (95% CIs)
Adjusted
odds ratios*
and (95% CIs)
Polypharmacy
-Never (ref) 1.0 1.0
-Ever 19.4 (19.2-19.7) 18.2 (18.0-18.4)
Age (years)
-70–74 (ref) 1.0 1.0
-75–80 1.0 (1.0- 1.0) 0.9 (0.9-0.9)
-81–85 0.8 (0.8-0 .8) 0.8 (0.8-0.8)
- > 85 0.3 (0.3-0.3) 0.4 (0.4-0.4)
Gender
-Male (ref) 1.0 1.0
-Female 1.0 (1.0-1.0) 0.9 (0.9- 0.9)
-Missing 1.5 (1.5-1.5)
Mobidities
(Charlson morbidity index score)
-1 (ref) 1.0 1.0
-2 2.2 (2.2-2.3) 1.51 (1.5-1.5)
-3 0.4 (0.4-0.40) 0.9 (0.9-0.9)
*Adjusted for age (70–74, 75–80, 81–85,>85 years), gender, morbidity (charlson
morbidity index: 1 representing a lower number of comorbidities and 3 higher)
and polypharmacy (ever/never).
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attempted to account for such misrepresentation, it is
still possible that therapeutic duplication was over-
estimated. Some patients may have belonged to practices
that were inactive, or had transferred out of CPRD
resulting in some data some loss during the study
period. This could have potentially led to a slight under-
estimation of PIP.
Conclusions
PIP is prevalent among older people across the UK, and
is more accurately estimated by applying a comprehen-
sive set of STOPP criteria to databases such as CPRD,
compared to the truncated version used in previous
studies, on more limited databases. However, compari-
son with previously published studies which had used a
subset of the full STOPP criteria showed examples of
PIP were consistent. Indicators such as the STOPP cri-
teria and the newly updated Beers criteria [42] have their
place in determining the presence of PIP and informing
interventions to reduce the problem. However, it appears
that more integrated approaches are needed to signifi-
cantly reduce the burden of PIP. Previously suggested
approaches in the UK have included identifying the main
PIP issues nationally (which this study fulfilled) and the
use of alert systems in the computers of primary care
physicians to identify PIP at the time of prescribing [43].
Such systems have effectively reduced the level of newly
prescribed inappropriate medications in the US [44] and
similar pharmacist-led information technology interven-
tions in the UK reduced medication errors in primary
care, indicating the potential for future development
[45]. It would appear from this study and previous
findings [16,17] that there is a need for targeted inter-
ventions to reduce PIP across all regions but especially
in NI and ROI. Targeted interventions focus on specific
instances of PIP. The UK has, in the past, successfully
introduced incentives to reduce inappropriate prescri-
bing of particular drug groups such as benzodiazepines
and these appear to have been successful in reducing the
overall burden of PIP. The introduction of national
guidelines on the prescribing of co-proxamol success-
fully led to reductions in the use of this preparation,
resulting in its eventual discontinuation [46]. Such tar-
geted interventions may provide a template for action in
the other regions where PIP is higher and for some of
the more common examples such as inappropriate use
of PPIs. Polypharmacy appears to be a major influence
on PIP, although attempts to reduce polypharmacy may
prove challenging due to the current emphasis on chronic
disease management in primary care.
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